<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025480</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068965</org_study_id>
    <secondary_id>UPCC-NCI-5150</secondary_id>
    <secondary_id>NCI-5150</secondary_id>
    <nct_id>NCT00025480</nct_id>
  </id_info>
  <brief_title>Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Trial of Farnesyltransferase Inhibitor, R115777 (NSC # 702818) and Radiotherapy in Patients With Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <brief_summary>
    <textblock>
      RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by making tumor cells more sensitive to radiation therapy.&#xD;
      Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy,&#xD;
      such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells&#xD;
      either by killing the cells or by stopping them from dividing and may also make tumor cells&#xD;
      more sensitive to radiation therapy.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of tipifarnib when&#xD;
      given together with radiation therapy after combination chemotherapy in treating patients&#xD;
      with stage III non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxicity of tipifarnib given&#xD;
           concurrently with radiotherapy after induction chemotherapy comprising paclitaxel and&#xD;
           carboplatin and followed by maintenance therapy with tipifarnib in patients with stage&#xD;
           IIIA or IIIB non-small cell lung cancer.&#xD;
&#xD;
        -  Determine the tumor response at 3 months in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is multicenter, dose-escalation study of tipifarnib.&#xD;
&#xD;
      Patients receive induction chemotherapy comprising carboplatin IV over 30 minutes on day 1&#xD;
      and paclitaxel IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 2&#xD;
      courses.&#xD;
&#xD;
      Beginning 4-6 weeks after the completion of induction chemotherapy, patients receive oral&#xD;
      tipifarnib twice daily for 7 weeks. Patients undergo radiotherapy once daily 5 days a week&#xD;
      for 7 weeks beginning 3 days after the start of tipifarnib. After completion of radiotherapy,&#xD;
      patients receive oral tipifarnib twice daily for 4 days and then once daily for 4 days.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of tipifarnib while receiving radiotherapy&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Beginning 4-6 weeks after the completion of radiotherapy and tipifarnib, patients receive&#xD;
      maintenance therapy comprising oral tipifarnib twice daily on days 1-21. Maintenance therapy&#xD;
      repeats every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 3, 6, and 12 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 9-12 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tipifarnib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer&#xD;
&#xD;
               -  Locally advanced (stage IIIA or IIIB) disease requiring radiotherapy&#xD;
&#xD;
          -  No malignant pleural effusion&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  No grade 2 or greater elevation of liver function tests&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times normal&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV_1 at least 600 cc&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No grade 3 or 4 peripheral neuropathy&#xD;
&#xD;
          -  No known allergy to imidazole drugs (e.g., ketoconazole, miconazole, econazole, or&#xD;
             terconazole)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Up to 2 prior or concurrent carboplatin and paclitaxel chemotherapy regimens allowed&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior thoracic radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 3 weeks since prior exploratory thoracotomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Michael Hahn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

